Kenvue (KVUE) Expected to Release Earnings on Friday

Kenvue (NYSE:KVUE) is expected to be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect Kenvue to announce earnings of $0.2915 per share and revenue of $3.86 billion for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 9:30 AM ET.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. During the same period last year, the company earned $0.29 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, analysts expect Kenvue to post $1.14 EPS for the current fiscal year and $1.23 EPS for the next fiscal year.

Kenvue Stock Down 0.6%

KVUE stock opened at $19.31 on Thursday. Kenvue has a twelve month low of $14.02 and a twelve month high of $20.13. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The stock’s 50 day moving average is $18.39 and its 200-day moving average is $18.16. The firm has a market capitalization of $37.09 billion, a PE ratio of 22.20, a P/E/G ratio of 1.79 and a beta of 0.48.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a dividend of $0.21 per share. The ex-dividend date was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.3%. Kenvue’s dividend payout ratio is 96.55%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. UBS Group decreased their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. HSBC cut their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Thirteen investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.33.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.